UCB
UCB Trial on the
Safety and Efficacy of Staccato Alprazolam
The STARS Study
The STARS Study is testing an inhaler containing an investigational drug to see whether it could help people who experience prolonged epileptic seizures. Two versions of the inhaler will be compared in this study: one version will contain the active investigational drug; the other version will contain a placebo. Both versions of the inhaler look identical, but the placebo version contains no active medication. All participants must collaborate with a study partner to assist them throughout the study.
Clinical Trial - Staccato Alprazolam
- Drug Candidate: Staccato Alprazolam
- Clinical Sponsor: UCB
- Trial Name: STARS
- Gene Eligibility: All patients with the required seizure type (not gene-specific)
- Age Eligibility: 12 years of age and older
- Seizure Requirement: Yes. Patients must have occasional prolonged seizures such as a focal seizure of at least 3 minutes, or a cluster of myoclonic/absence seizures for at least 5 minutes.
- Will patients on placebo get access to the drug candidate? All participants in the follow-up STARS Extension trial (NCT05076617) receive the active drug for home use.
- Sites Currently Open (Recruiting): USA (Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Louisiana, Massachusetts, Maryland, Michigan, Minnesota, Missouri, North Carolina, Nebraska, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin), Canada, Australia, Europe (Austria, Czechia, Finland, France, Germany, Israel, Netherlands, Poland, Spain, Switzerland, UK).
- To Learn More: Contact Information: To learn more about the STARS study, you can visit the study-specific website www.starsepilepsystudy.com.
